VivoSeq
Psychiatry

Depressive Symptoms

0

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Depressive Symptoms is an early-stage landscape with 0 programs across 3 companies. The most active players are Boehringer Ingelheim, Axsome Therapeutics, Inc., Institut de Recherches Internationales Servier.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalA

Axsome Therapeutics, Inc.

0 programs

PreclinicalInstitut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Completed12 · 55%
Recruiting4 · 18%
Terminated2 · 9%
Unknown status1 · 5%
Active, not recruiting1 · 5%
Withdrawn1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

22 trials

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Recruiting·NNHS Greater Glasgow and Clyde·N/A·NCT06786936·50 enrolled
Going to Altitude With Anxious-depressive Symptoms
Recruiting·—·N/A·NCT05323864·68 enrolled
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Recruiting·AAxsome Therapeutics, Inc.·Phase 4·NCT06223880·350 enrolled
Feasibility and Effects of a Blended Baduanjin Exercise and Green Tea Consumption Program on Depressive Symptoms, Gut Microbiota and Quality of Life in Older Adults: A Randomized Controlled Trial
Recruiting·HHong Kong Baptist University·Preclinical·NCT07687940·48 enrolled
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Active, not recruiting·NNew York State Psychiatric Institute·Phase 2·NCT05690503·12 enrolled
Esketamine and Perioperative Depressive Symptoms
Completed·—·Phase 2/3·NCT04425473·435 enrolled
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
Completed·EEmory University·Phase 4·NCT00352885·20 enrolled
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
Completed·NNew York State Psychiatric Institute·Phase 4·NCT01973283·100 enrolled
NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression
Completed·—·Phase 2·NCT02294591·80 enrolled
Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
Completed·WWashington University School of Medicine·Phase 3·NCT05233566·32 enrolled
The Effect on Depressive Symptoms in ECF Residents With COPD
Completed·VValley Medical Research·Phase 4·NCT00974246·30 enrolled
Profile of Depressive Symptoms in Parkinsons Disease
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT00349310·1,018 enrolled
Nexalin Therapy for the Treatment of Depressive Symptoms
Completed·KKalaco Scientific, Inc.·Phase 2·NCT00774813·120 enrolled
Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment.
Completed·IInstituto Mexicano del Seguro Social·N/A·NCT03473431·90 enrolled
Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion
Completed·—·Phase 4·NCT06060210·110 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)